From Financial Modeling Prep: 2025-05-12 16:00:00

Nyxoah S.A. (NASDAQ:NYXH) is a medical technology company specializing in sleep apnea solutions, notably the Genio® system. With upcoming quarterly earnings on May 13, 2025, analysts predict an EPS of -$0.49 and revenue around $1.64 million. Financial ratios reveal Nyxoah’s lack of profitability, with a high price-to-sales ratio of 41 and low debt-to-equity ratio of 0.20.

Despite Nyxoah’s negative earnings yield of -29.67%, the company boasts a strong current ratio of 4.56, indicating solid liquidity. Nyxoah’s enterprise value to sales ratio of 38.44 reflects investor optimism for future growth. While facing a securities fraud investigation, Nyxoah received an FDA Approvable Letter for its Genio® system, marking regulatory progress.



Read more at Financial Modeling Prep:: Nyxoah S.A. (NASDAQ:NYXH) Earnings Preview and Fin…